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Background: Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy
of cabazitaxel is based on body surface area (BSA). Body surface area is known as a poor predictor for total systemic exposure to
drugs, since it does not take into account variability in activity of metabolising enzymes, necessary for clearance of drugs. As
exposure to cabazitaxel is related to treatment response, it is essential to develop a better individualised dosing strategy.
Methods: Ten patients with metastatic castration-resistant prostate cancer, who received cabazitaxel dosed on BSA as a part of
routine palliative care, were enrolled in this study. Midazolam was administered as phenotyping probe for cytochrome P450
isoenzyme 3A (CYP3A). The relationship between midazolam and cabazitaxel clearance was investigated using non-linear mixed
effects modelling.
Results: The clearance of Midazolam highly correlated with cabazitaxel clearance (R¼ 0.74). Midazolam clearance significantly
(Po0.004) explained the majority (B60%) of the inter-individual variability in cabazitaxel clearance in the studied population.
Conclusions: Metabolic phenotyping of CYP3A using midazolam is a promising strategy to individualise cabazitaxel dosing.
Before clinical application, a randomised study is warranted.
Cabazitaxel is a novel drug from the class of taxanes that is
approved for treatment of men with castration-resistant metastatic
prostate cancer who have previously been treated with docetaxel
(de Bono et al, 2010). Like other taxanes, cabazitaxel acts by
binding to tubulin, and thereby stabilising the microtubules which
leads to inhibition of the mitotic cellular functions (NDA, 2013).
Cabazitaxel is 80–90% metabolised by the cytochrome P450
isoenzyme 3A (CYP3A), and a part of the remaining drug is
metabolised by CYP2C8. Seventy-six per cent of the inactive
metabolites are excreted via the faecal route and 4% by the renal
system. Only a small fraction of the active drug, 2.3%, is found
unchanged in the urine (NDA, 2013).
Treatment with cabazitaxel is often associated with considerable
and dose-limiting side-effects, like neutropenia and diarrhoea.
In daily practice, diarrhoea and neutropenia seem to be less
pronounced than mentioned in the registration trial (Heidenreich
et al, 2013; Nieuweboer et al, 2016). A post hoc analysis of the
registration trial showed that the occurrence of neutropenia during
treatment with cabazitaxel is associated with survival benefit
(Meisel et al, 2016). Although this finding has not been confirmed
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prospectively, it does indicate that there is a fine balance between
toxic and subtherapeutic exposure. This is supported by the finding
that cabazitaxel-induced grade X3 neutropenia is positively
correlated with systemic exposure (NDA, 2013). Similar to other
chemotherapeutics, cabazitaxel is dosed based on body surface area
(BSA), while BSA only partly explains the variability in cabazitaxel
clearance (NDA, 2013; Ferron et al, 2013). In 1958, Pinkel et al,
proposed to use BSA as the criterion of dosage in chemotherapy
(Pinkel, 1958). Although widely used, the appropriateness of
BSA-based dosing for anticancer agents is under heavy debate
(Anderson and Holford, 2009; Chatelut et al, 2012; Bins et al,
2014). For example, BSA is a poor predictor of clearance in obese
and underweight patients (Anderson and Holford, 2008). Further-
more, variability in activity and expression of metabolising
enzymes and drug transporters are only partially explained by
body size (Undevia et al, 2005; Mathijssen et al, 2014). Therefore,
other dose individualisation strategies with cytotoxic drugs have
been employed, such as ‘therapeutic drug monitoring’ (TDM) (de
Jonge et al, 2005), where dose adaptations are performed based on
measurement of drug concentrations after administration of the
drug. As early toxicity or subtherapy is unwanted, the inherent
downside of therapeutic drug monitoring is that dose individua-
lisation cannot take place until a therapeutic dose has been
administered, and steady state has been established. An attractive
alternative to individualise dosing of cytostatic drugs is by means
of metabolic phenotyping (Mathijssen and van Schaik, 2006;
Opdam et al, 2012): drug disposition of an anticancer drug can be
predicted by studying the disposition of a relatively harmless probe
drug. The pharmacokinetics of this phenotypic probe drug can
then be used to individualise dosing from the first dose onwards.
Metabolic phenotyping to individualised dosing has proven to be
successful for different cytotoxic agents, including the taxane
docetaxel (Opdam et al, 2012). The activity of the isoenzyme
CYP3A is notoriously variable between individuals (de Wildt et al,
1999), and can be metabolically phenotyped with the probe drug
midazolam (Oneda et al, 2009). Up to 90% of the metabolism of
cabazitaxel is accounted for by CYP3A, with CYP2C8 likely to be
responsible for the majority of the remaining metabolism (Ridoux
et al, 2015). Furthermore, although it is known that cabazitaxel
may be a substrate for efflux transporters from the ATP-binding
cassette family, it is in a lesser extent than its structural analogue
docetaxel, which may also partly explain why cabazitaxel is still
efficacious in patients who have progressive disease after docetaxel
treatment (Oprea-Lager et al, 2013; Duran et al, 2015; Kathawala
et al, 2015; Tang et al, 2015).
As cabazitaxel is mainly metabolised by the hepatic CYP3A
isoenzyme, metabolic phenotyping with midazolam could be a
good strategy to improve individualised dosing. Therefore, we
performed a proof-of-concept study to investigate the correlation
of midazolam clearance with cabazitaxel clearance and to compare
the performance of CYP3A metabolic phenotype and BSA to
predict pharmacokinetic variability in cabazitaxel clearance, and
thus systemic exposure.
MATERIALS AND METHODS
This proof-of-concept pharmacokinetic study was performed at
Meander Medical Center in Amersfoort, the Netherlands. The
study was approved by the medical ethics committee (MEC-U,
Nieuwegein, The Netherlands) and all patients provided their
informed consent. Ten men with metastasised castration-resistant
prostate cancer, who were already scheduled to receive cabazitaxel
as a part of routine clinical care, were included in the study.
Cabazitaxel was administered at the approved dose of 25mgm 2.
Body surface area for each patient was calculated according to the
Dubois and Dubois formula (du Bois and du Bois, 1916). For
purposes of metabolic phenotyping, the patients received a flat
dose of 2.5mg as an intravenous shot of midazolam, followed by a
shot of 5ml of NaCl 0.9%, at 1-7 days prior to chemotherapy
treatment. The intravenous route was chosen deliberately, as it
bypasses first-pass metabolism and better resembles the metabolic
fate of cabazitaxel. Just prior to the infusion of midazolam (time
point 0) and at 30, 60, 120, 240 and 360min after, blood samples
were collected from a venous cannula in the opposite arm. On the
day of cabazitaxel treatment, several blood samples were collected
before (time point 0) and at 30, 60, 120, 240, 360, 600min after
infusion of cabazitaxel. In addition, a blood sample was collected
24 hours after the cabazitaxel infusion. For the determination of
plasma drug concentrations, blood samples of 5ml were obtained
to collect at least 2ml of plasma in a vacuum collection tube with
EDTA as an anticoagulant. Immediately after blood collection, the
blood plasma was separated from the erythrocytes by means of
centrifugation and plasma was stored at  30 1C until further
analysis.
Bioanalytics and pharmacokinetic analysis. Frozen plasma
concentrations of cabazitaxel and midazolam were shipped
to the laboratory of Translational Pharmacology (Rotterdam,
The Netherlands) and quantified using validated liquid chromato-
graphy tandem mass spectrometry assays (de Bruijn et al, 2012).
The limits of quantification for midazolam and cabazitaxel were
0.4 ngml 1 and 1 ngml 1, respectively. The inter- and intra-run
precisions were less than 12.5% for midazolam and less than 9% for
cabazitaxel. The accuracies for both assays were within 12% of the
nominal concentrations.
Modelling was performed by means of non-linear mixed effects
modelling, using the software program NONMEM V7.3.0, inter-
faced with Perl Speaks Nonmem, R and Xpose (Keizer et al, 2013).
The first order conditional estimation method with interaction was
used and parameter precision was obtained using the covariance
step. Throughout model building, standard goodness of fitness
plots and prediction-corrected visual predictive checks (Bergstrand
et al, 2011) were explored to assess the developed model. First, two
separate pharmacokinetic models for midazolam and cabazitaxel
were developed that captured the inter-individual variability in
clearance. Thereafter, the individual empirical Bayes estimates for
midazolam clearance were investigated as covariate for cabazitaxel
clearance.
Midazolam clearance was investigated as a continuous covariate
for cabazitaxel clearance using linear, power and exponential
functions, as described previously (Joerger, 2012).
Midazolam clearance was considered for inclusion in the final
model if the model fit improved significantly, and if it reduced the
unexplained inter-individual variability in cabazitaxel clearance.
In our analysis, Po0.05 was considered significant, corresponding
with a reduction in objective function of 3.84 points or more as a
critical w2-value.
RESULTS
Patient characteristics. Ten patients with metastatic castration-
resistant prostate carcinoma treated with cabazitaxel were included
in the study. All patients received prior treatment with docetaxel
(Table 1). The median age of the participants was 67 (range 65–77)
years. Median BSA of the patients was 1.95m2 (range 1.76–
2.34m2). Median dose of administered cabazitaxel was 46.25mg
(range 38–50mg). Hepatic function as measured with bilirubin was
not decreased in any of the patients. During treatment, in 50% of
the patients a decrease in PSA with 50% was seen. Also, 50% of the
patients reported diarrhoea during treatment. None of these
patients had to be admitted to the hospital due to diarrhoea, nor
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needed the dose to be adjusted. One patient had to be admitted due
to neutropenic fever. None of the patients had to stop treatment
because of toxicity.
Pharmacokinetic modeling. Midazolam pharmacokinetics were
highly variable and best described with a first order one
compartment linear pharmacokinetic model (Figure 1). The model
parameter estimates are presented in Table 2A. Inter-individual
variability in midazolam clearance and volume of distribution
were high at 73.2% and 77.3%, respectively. Standard goodness
of fit plots of the pharmacokinetic model for midazolam and
the prediction-corrected visual predictive check are provided as
Supplementary Files with this manuscript (Supplementary Figures
1–3). Cabazitaxel pharmacokinetics were best described with a
linear two compartment pharmacokinetic model (see Figure 1 and
Table 2B). Unexplained inter-individual variability in clearance of
cabazitaxel was moderate at 24.8%. The limited eta-shrinkage
(o10%) for midazolam and cabazitaxel clearance showed that data
were informative to describe variability in these parameters (Savic
and Karlsson, 2009).
Upon visual inspection of the empirical Bayes estimates of
cabazitaxel clearance vs midazolam clearance (Figure 2), a high
correlation could be observed. When midazolam clearance
was tested as a covariate for cabazitaxel clearance using linear,
exponential and power functions, a linear function (Equation (1))
best described the relationship between midazolam clearance and
cabazitaxel clearance: approximately 60% of the unexplained inter-
individual variability of cabazitaxel clearance was explained, and
it reduced significantly (P¼ 0.004) from 24.8 to 10.2%. The
parameter estimates for the cabazitaxel pharmacokinetic model,
including midazolam clearance as a linear covariate, are presented
in Table 2B. As observed, the shrinkage in cabazitaxel clearance
increased, confirming that midazolam clearance accounted for the
majority of the observed variability in cabazitaxel clearance.
CL ¼ CLbase þ½ CLmdz;i CLmdz;pop
 yclearance ð1Þ
In this Equation, CL is the cabazitaxel clearance (l h 1), CLbase is
the typical value for cabazitaxel clearance (119 l h 1) in an
individual with a midazolam clearance (CLmdz,i) that equals the
population value for midazolam clearance (CLmdz,pop) of 26 l h
 1
and yclearance is the gradient of 1.71 that describes the relation-
ship between midazolam and cabazitaxel clearance.
Figure 2 shows the model-derived relationship between the
empirical Bayes estimates for midazolam and cabazitaxel clearance
from the base models. As observed, midazolam clearance highly
correlated with cabazitaxel clearance (R¼ 0.74). Midazolam
clearance was therefore retained in the final model as a covariate
for cabazitaxel clearance. Figure 3 shows the prediction-corrected
visual predictive check for the final model, including individual
midazolam clearance as covariate for cabazitaxel clearance. As
observed in this figure, the observed data correspond well with the
simulated data (based on 1000 simulations), showing the internal
validity of our model.
DISCUSSION
The variability in pharmacokinetics of both midazolam and
cabazitaxel are greatly explained by variability in the CYP3A
enzymatic activity. Since both drugs act as substrates for CYP3A,
we hypothesised that the clearance of cabazitaxel could be
predicted by the clearance of midazolam. In cancer patients it is
known that CYP3A4 activity varies about four-fold between
patients (Lepper et al, 2005; Mathijssen et al, 2014), based on
genetic and environmental factors. In our opinion individualised
dosing strategies for drugs metabolised through this phase I
enzyme should take this variation into account.
In our proof-of-concept study, we showed that midazolam
clearance and cabazitaxel clearance were highly correlated. This
indicates that midazolam can be a useful phenotypic probe to
individualise cabazitaxel dosing. The unexplained variability of
cabazitaxel clearance in our population was in the same order of
magnitude as found in previous large population pharmacokinetic
study (Ferron et al, 2013). In this study BSA and cancer type
together accounted for only a small part (19%) of the observed
inter-individual variability in cabazitaxel clearance. As metabolic
phenotype appears to explain a much larger part of the inter-
individual variability in cabazitaxel clearance, this suggests that
midazolam has the potential to better individualise cabazitaxel
clearance than BSA. As observed in Figure 2, the intercept with the
Y-axis of our model-derived relationship suggests clearance of
cabazitaxel when midazolam clearance is 0. Although the exact
Table 1. Patient characteristics
Range
Number of included patients 10
Median age 67 (65–77)
Median dose of cabazitaxel 46.25mg (38–50mg)
Median BSA 1.96m2 (1.76–2.34m2)
Billirubin, median 8.5 mmol l1 (5–15 mmol l1)
PSA, median 435 mg l 1 (13–902mg l 1)
Percentage
Previous prostate cancer treatment 10 100%
Chemotherapy
Docetaxel 10 100%
Hormone therapy
Orchidectomy 2 20%
Goserelin acetate 8 80%
Bicalutamide 9 90%
Abiraterone acetate 3 30%
Other
Prostatectomy 0 0%
External beam radiotherapy on prostate 1 10%
Bone seeking radionuclide treatment 9 90%
Patient characteristics at time of inclusion.
Dose
1 h iv infusion
Dose
iv bolus
Cabazitaxel
Peripheral (V2)
Cabazitaxel
Central (V1)
Midazolam
Central (V3)
Q/V1
Q/V2
* CL = CLbase + [(CLmdz,i – CLmdz,pop)*θclearance]
CLCBZ/V*1 CLMDZ/V3
Figure 1. Pharmacokinetic models for midazolam and cabazitaxel.
Schematic representation of the pharmacokinetic models for
midazolam and cabazitaxel. CLbase¼ clearance of cabazitaxel in the
base model, CLCBZ¼ clearance of cabazitaxel, CLmdz¼ clearance of
midazolam, CLmdz,i¼ clearance of midazolam individual,
CLmdz,pop¼Clearance of midazolam population,
Q¼ intercompartmental clearance, V1¼ volume of distribution of the
central compartment of cabazitaxel, V2¼Volume of distribution of the
peripheral compartment of cabazitaxel, V3¼Volume of distribution of
the central compartment of midazolam, yclearance¼gradient of the
correlation between the clearance of midazolam and cabazitaxel.
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reason for this phenomenon remains uninvestigated, it may be
partly accounted for by the fact that a small portion (o10%) of
cabazitaxel is metabolised by the enzyme CYP2C8 (NDA, 2013;
Ridoux et al, 2015), an enzyme that is not involved in midazolam
metabolism.
Our findings are in line with previous studies that showed
that midazolam clearance predicts the clearance of different
anticancer drugs that share a metabolic pathway with midazolam
(Goh et al, 2002; Mathijssen et al, 2004; de Wit et al, 2014),
although the correlation between midazolam and these anticancer
agents studied in these previous studies was weaker compared
to the current study. Potentially, the role of CYP3A in cabazitaxel
metabolism is of larger importance compared to the other com-
pounds studied (i.e., irinotecan, docetaxel and sunitinib). Although
the latter has been shown for several different chemotherapeutics
(Mathijssen and van Schaik, 2006), dosing strategies based on BSA
are still used daily in clinical practice. This has to do with a lack of
confirming studies where the use of phenotype-based dosing
strategy actually leads to better clinical results. However, although
also a logistical challenge, therapeutic drug monitoring-based
dosing strategy for cabazitaxel is currently tested in a prospective
randomised phase II trial (CAINTA trial, EudraCT number:
2013-005504-34).
A limitation of our study was that the number of studied patients
was small. For implementation of a metabolic phenotype-based
dosing strategy, therefore, some hurdles have to be overcome. First, to
obtain a more reliable estimate of the relationship between metabolic
phenotype and cabazitaxel pharmacokinetics, the relationship should
be studied in a larger population. Second, since sampling a full
pharmacokinetic curve of midazolam to establish the metabolic
phenotype is not very feasible in routine clinical practice, a limited
sampling strategy should be developed, as previously proposed
(Katzenmaier et al, 2010). Lastly, a prospective study comparing
routine BSA-based dosing vs metabolic phenotype-based dosing
should be performed on clinical and pharmacokinetic end points.
NeutropeniaXgrade 3 was the most seen severe complication in
the registration trial of cabazitaxel, with an incidence of 82%
(de Bono et al, 2010). Although later performed safety studies
showed drastically lower incidence numbers of neutropenia
(7.2–33.9%), neutropenia was still the most frequent severe
complication observed (Heidenreich et al, 2013; Bracarda et al,
2014). The occurrence of severe neutropenia is mentioned to
correlate with the AUC of cabazitaxel (NDA, 2013). A post hoc
analysis of the registration trial showed that the occurrence of
gradeX3 neutropenia was associated with an increased overall
survival and progression free post hoc survival (Meisel et al, 2016).
Table 2. Model parameters estimates of the pharmacokinetic
models for midazolam (A) and cabazitaxel (B) (see also
Figure 1)
(A)
Parameter Final model
Estimate (% RSE) (shrinkage))
V3 75.4 l (24.8%) (0.3%)
CLmdz 26.0 l h
 1 (25.0%) (0.1%)
IIV V3 77.3% (80.4%)
IIV CLmdz 73.2% (53.7%)
Residual error 35.4% (40.6%) (20.5%)
(B)
Parameter Base model
Metabolic
phenotype model
Estimate (% RSE)
(shrinkage)
Estimate (% RSE)
(shrinkage)
V1 142 l (26.0%) 142 l (35.1%)
V2 2050 l (29.7%) 2090 l (30.2%)
Q 220 l h1 (15.0%) 220 l h1 (47.9%)
CLCBZ 129 l h
1 (23.6%) 119 l h1 (29.6%)
yclearance — 1.71 (69%)
IIV CLCBZ 24.8% (128.1%)
(10.6%)
10.2% (294.2%)
(41.7%)
Residual error 33.0% (20.4%) (5.4%) 33.3% (19.7%)
(2.3%)
Drop in objective function Not applicable 8.1 (P¼ 0.004)
Abbreviations: CLCBZ¼ clearance of cabazitaxel, CLmdz¼ clearance of midazolam, IIV¼
inter-individual variability, Q¼ intercompartmental clearance, RSE¼ relative standard error,
V1¼ volume of distribution of the central compartment of cabazitaxel, V2¼Volume of
distribution of the peripheral compartment of cabazitaxel, V3¼Volume of distribution of the
central compartment of midazolam, yclearance¼gradient of the correlation between the
clearance of midazolam and cabazitaxel.
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Figure 2. Relationship between individual estimates for clearance of
midazolam and cabazitaxel. Empirical Bayes estimates for midazolam
and cabazitaxel clearance (black dots) and their model-predicted
relationship (dotted line) from the final model.
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Figure 3. Prediction-corrected visual predictive check of cabazitaxel
final model. The prediction-corrected simulated (shaded areas) and
observed (circles and lines) cabazitaxel concentrations vs time (h),
based on 1000 simulations are shown. The thick black line connects the
observed median values per bin. The dotted grey lines connect the 5th
and 95th percentiles of the observations. The light grey areas are the
95% confidence interval of the 5th and 95th percentiles. The dark grey
area indicates the confidence interval of the median.
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In this group of patients with gradeX3 neutropenia, a greater
decrease in PSA levels was also observed, compared with the
patients with milder or no neutropenia (Meisel et al, 2016). This
phenomenon, where the occurrence of neutropenia is a positive
predictor for survival, has been described for various solid
and haematological malignancies (Brosteanu et al, 2004; Di Maio
et al, 2005), and is an indirect marker for the pharmacokinetic-
pharmacodynamic relationship of cytotoxic agents. Because the
results of those post hoc analyses have not been prospectively
confirmed, and since neutropenia can also be harmful for the
patient, these results should be interpreted with great caution.
However, these studies indirectly show that relatively high
exposure might lead to toxicity, such as neutropenia, but this high
exposure is on the other hand also probably correlated with
survival. Therefore, prevention of subtherapeutic exposure seems
to be of utmost importance. Phenotypically guided dosing
strategies may decrease the number of patients who are under-
dosed with the current BSA drug dosing paradigm.
In our proof-of-concept study, we have shown that midazolam-
based metabolic phenotyping may be a valuable tool to indivi-
dualise cabazitaxel dosing. Besides using metabolic phenotyping to
predict the correct starting dose, other strategies like toxicity and
drug level monitoring to guide following doses may be employed to
further tailor cabazitaxel therapy. If future trials support the
hypothesis that phenotype-based dosing increases outcome and
decreases side-effects there will be a real alternative for the long
used BSA dosing strategy.
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